Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223125 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
A Phase 1 study of Advanced-stage Solid Tumors, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 360
- Enrollment target
- 5
- Study locations
NCT07223125: Recruiting Phase 1 study of Advanced-stage Solid Tumors, sponsored by Janssen Research & Development.
NCT07223125 is a Phase 1 study of Advanced-stage Solid Tumors that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 360 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (500% higher). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223125, a Phase 1 study of Advanced-stage Solid Tumors, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 360 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Primary Outcome
The DLTs are specific adverse events that includes high grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation.
Conditions Studied
Interventions
- DRUG JNJ-89862175
Study Locations (5)
Other
- Centre Leon Berard - Lyon
- Gustave Roussy - Villejuif
- Samsung Medical Center - Seoul
Florida
- AdventHealth Orlando - Orlando
Texas
- NEXT Oncology - Irving
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2028-08-15 |
| Phase | Phase 1 |
What NCT07223125 shows while recruiting
NCT07223125 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (500% higher).
The record links to 1 condition, with Advanced-stage Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JNJ-89862175 is the first listed.
NCT07223125 lists 5 locations in 3 states (Other, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT07223125 about?
NCT07223125 is a clinical study titled "A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors". The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
What is the current status of trial NCT07223125?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 360 participants. The study started on 2025-10-10. Estimated completion is 2028-08-15.
What conditions does trial NCT07223125 study?
This clinical trial studies the following conditions: Advanced-stage Solid Tumors.
What interventions are being tested in trial NCT07223125?
The interventions under investigation include: JNJ-89862175 (DRUG).
Who is sponsoring clinical trial NCT07223125?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223125 being conducted?
This trial has 5 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07223125's enrollment target sits among peer trials
360 91st of 2000 higher than 1,908 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI